BioLineRx Enters into $5.6 Million Royalty Monetization Transaction with Soleus Capital
- Transaction provides non-dilutive capital through sale of BioLineRx's portion of future APHEXDA royalties - - Funds to support clinical development of GLIX1, including ongoing Phase 1/2a clinical trial, which is currently enrolling the fourth of five planned dosing cohorts - - BioLineRx...